Brief: Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for Apabetalone
01/11/2017 12:00
Nov 1 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces fifth positive recommendation from
Data
Safety Monitoring Board for phase 3 study of Apabetalone
* Resverlogix - independent DSMB recommended phase 3 study
of
Apabetalone should continue as planned without modifications
* Resverlogix Corp - full enrollment for phase 3 study of
apabetalone now anticipated in first half of 2018
Source text for Eikon: ID:nGNXOGMZIa
Further company coverage: RVX.TO
(Bangalore.newsroom@thomsonreuters.com)
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment